Document is current
Any future updates will be listed below
-
Authors
Krebs, Kristi
Luitva, Laura Birgit
Kõre, Anette Caroline
Kokasaar, Raul
Jõeloo, Maarja
Hudjashov, Georgi
Maal, Kadri
Størset, Elisabet
Wollmann, Birgit Malene
Karo-Astover, Liis
Fischer, Krista
Team, Estonian Biobank Research
Lauschke, Volker M.
Ingelman-Sundberg, Magnus
Molden, Espen
Irs, Alar
Oselin, Kersti
Lass, Jana
Milani, Lili
-
Funding
Funding for this research was provided by:
Knut och Alice Wallenbergs Stiftelse (WASPDDLS22:006)
Vetenskapsrådet (2021-02732)
Eesti Teadusagentuur (PRG2625)
European Commission (SafePolyMed)
- License Information
-
More Information
Article History
Received: 21 July 2025
Accepted: 29 December 2025
First Online: 18 January 2026
Competing interests
: V.M.L. is CEO and shareholder of HepaPredict AB, as well as co-founder and shareholder of Shanghai Hepo Biotechnology Ltd. M.I.S. is a co-founder and co-owner of HepaPredict AB. Other authors declare that they have no competing interests.
